ClinicalTrialsFinder

Triple-Negative Breast Cancer Clinical Trials in Boston, Massachusetts

19 recruitingBoston, Massachusetts

Showing 1–19 of 19 trials

Recruiting
Phase 3

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

Triple-Negative Breast Cancer
Gilead Sciences1,514 enrolled350 locationsNCT05633654
Recruiting
Phase 1Phase 2

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Triple-Negative Breast CancerEndometrial CancerPrimary Peritoneal Carcinoma+12 more
Genmab884 enrolled66 locationsNCT05579366
Recruiting
Phase 1

A Study of LY4175408 in Participants With Advanced Cancer

Triple-Negative Breast CancerCarcinoma, Non-Small Cell LungNeoplasm Metastasis+2 more
Eli Lilly and Company240 enrolled27 locationsNCT07046923
Recruiting
Phase 2

Sacituzumab Govitecan In TNBC

Triple-Negative Breast CancerHER2-negative Breast CancerInvasive Breast Cancer+2 more
Massachusetts General Hospital260 enrolled5 locationsNCT04230109
Recruiting
Phase 1Phase 2

First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

TNBC - Triple-Negative Breast CancerAdvanced Solid TumorsNSCLC+3 more
Tubulis GmbH250 enrolled16 locationsNCT06657222
Recruiting
Phase 1

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Triple-Negative Breast CancerEsophageal CancerPancreatic Cancer+11 more
Eli Lilly and Company420 enrolled33 locationsNCT06465069
Recruiting
Phase 2

Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)

Breast CancerTriple-Negative Breast CancerCirculating Tumor DNA+1 more
Dana-Farber Cancer Institute40 enrolled7 locationsNCT04434040
Recruiting
Phase 2

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

Breast CancerTriple-Negative Breast CancerPD-L1 Negative
Dana-Farber Cancer Institute110 enrolled15 locationsNCT04468061
Recruiting
Phase 1

Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers

Triple-Negative Breast CancerColorectal, CancerNon-small Cell Lung Cancer+2 more
Novartis Pharmaceuticals162 enrolled31 locationsNCT06562192
Recruiting
Phase 1

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors

Triple-Negative Breast CancerGastric CancerOvarian Cancer+25 more
NiKang Therapeutics, Inc.150 enrolled19 locationsNCT06586957
Recruiting
Phase 1

A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Triple-Negative Breast CancerNon-small Cell Lung CancerHead and Neck Squamous Cell Carcinoma+2 more
Compass Therapeutics85 enrolled9 locationsNCT06150664
Recruiting
Phase 1

A Study of XMT-1660 in Participants With Solid Tumors

Breast CancerTriple-Negative Breast CancerOvarian Cancer+4 more
Mersana Therapeutics319 enrolled26 locationsNCT05377996
Recruiting
Phase 1

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

Triple-Negative Breast CancerColorectal, CancerBiliary Tract Cancer+8 more
Zumutor Biologics Inc.100 enrolled3 locationsNCT06451497
Recruiting
Not Applicable

Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer

Breast CancerTriple-Negative Breast CancerMetastatic Breast Cancer+3 more
Brigham and Women's Hospital214 enrolled1 locationNCT04030507
Recruiting
Phase 1

A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs

Triple-Negative Breast Cancer
Mabwell (Shanghai) Bioscience Co., Ltd.52 enrolled6 locationsNCT06908928
Recruiting
Phase 1Phase 2

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

Breast CancerTriple-Negative Breast CancerColorectal, Cancer+26 more
PMV Pharmaceuticals, Inc300 enrolled76 locationsNCT04585750
Recruiting
Phase 1

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Breast CancerTriple-Negative Breast CancerEsophageal Cancer+9 more
SystImmune Inc.470 enrolled39 locationsNCT05983432
Recruiting
Phase 1

Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies

Triple-Negative Breast CancerBreast NeoplasmsLung Cancer+7 more
Circle Pharma220 enrolled10 locationsNCT06577987
Recruiting
Phase 1Phase 2

Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067

Triple-Negative Breast CancerMelanomaCancer+6 more
Simcha IL-18, Inc.316 enrolled6 locationsNCT04787042